BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Low-profile mRNA developer Greenlight going public in $1.5B SPAC merger
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Low-profile mRNA developer Greenlight going public in $1.5B SPAC merger
Aug. 10, 2021
By
Lee Landenberger
No Comments
MRNA’s the thing and special purpose acquisition company (SPAC) Environmental Impact Acquisition Corp. is following as it will merge with privately held mRNA-developer Greenlight Biosciences Inc.
BioWorld
Deals and M&A
Coronavirus
Vaccine